Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Fineline Cube Jul 3, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Deals Medical Device

Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion

Fineline Cube Feb 17, 2023

Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...

Company Drug

NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis

Fineline Cube Feb 17, 2023

The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...

Company

Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines

Fineline Cube Feb 17, 2023

US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...

Company Deals Digital R&D

WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services

Fineline Cube Feb 16, 2023

China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...

Company

Eppendorf to Start Construction on New Shanghai Production Site

Fineline Cube Feb 16, 2023

Germany-based life sciences service provider Eppendorf is set to begin work on a new production...

Company Deals

InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement

Fineline Cube Feb 16, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...

Company Drug

AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan

Fineline Cube Feb 16, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...

Company Drug

Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis

Fineline Cube Feb 16, 2023

China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...

Company Drug

Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa

Fineline Cube Feb 16, 2023

Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...

Company Drug

Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma

Fineline Cube Feb 16, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...

Company Drug

Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases

Fineline Cube Feb 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047

Fineline Cube Feb 16, 2023

The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...

Company Drug

Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment

Fineline Cube Feb 16, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...

Company Deals

Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics

Fineline Cube Feb 16, 2023

US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...

Company Deals

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

Fineline Cube Feb 15, 2023

China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...

Posts pagination

1 … 586 587 588 … 690

Recent updates

  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.